Skip to main content

Refocusing the Multiple Sclerosis Treatment Landscape

September 16, 2020

logoEdmund Pezalla, MD, MPH, CEO, Enlightenment Bioconsult LLC, discusses treatment options for multiple sclerosis, highlights results from the ASCLEPIOS I and II studies, and notes why this data can be useful for payers.

Reference: Hauser SL, Bar-Or A, Cohen JA, et al. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med. 2020;383(6):546-557. doi:10.1056/NEJMoa1917246


Agree or disagree with an article? Share your professional thoughts on an article you read.

Your Name
15 + 5 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Back to Top